3SBio
三生制药
Executive Summary
3SBio is a Shenyang-based biotech that just completed one of the largest China-to-US licensing deals in history, licensing a bispecific antibody to Pfizer for $1.25B upfront and up to $4.8B total. The company demonstrates strong deal-making capability and pipeline quality, evidenced by securing the highest upfront-to-total ratio (26%) among mega-deals. With clear BIOSECURE status, 3SBio represents a lower-risk partnering opportunity for US pharma seeking to access innovative Chinese biotech assets.
Structure: 3SBio is a Hong Kong-listed entity (1530.HK) likely structured through a VIE arrangement typical of Chinese biotech companies accessing public markets. The company operates from Shenyang headquarters, suggesting core R&D and manufacturing operations are China-based, which will require standard VIE due diligence procedures for any significant partnership or investment.
Ownership & Shareholder Structure
Corporate Events
Pfizer-3SBio $4.8B licensing deal
Pfizer licensed bispecific antibody from 3SBio for $1.25B upfront, up to $4.8B total. Highest upfront-to-total ratio (26%) among mega-deals. Oncology/immunology bispecific.
Clinical Trials(1 total)
1
Phase 1
| NCT ID | Interventions | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06630494 | Recombinant human thrombopoietin for injection (rhTPO) | Ph.1 | COMPLETED | 22 |
BIOSECURE Risk
Company has clear BIOSECURE status and is not designated under BCC categories, indicating minimal regulatory exposure for US partnerships
Key Exposures:
- •Potential future regulatory changes
- •China-based operations and manufacturing
Mitigation: Clear regulatory status provides immediate partnering pathway with standard compliance monitoring
BD Intelligence
Therapeutic Areas:
Recent Deals: Landmark $4.8B licensing deal with Pfizer in May 2025 for bispecific antibody, representing one of the largest China-to-US biotech transactions and demonstrating exceptional deal execution capability
Approach: High-priority target for proactive outreach given proven deal readiness and pipeline quality. Focus on remaining oncology/immunology assets and establish relationship for future opportunities.
Red Flags
- ⚠Limited public information on key management and corporate structure
- ⚠Recent mega-deal may have depleted most attractive assets
- ⚠China-based operations require standard geopolitical risk monitoring
Quick Facts
- Key People
- 0
- Subsidiaries
- 0
- CDMO/CRO Subs
- 0
- Genomics Subs
- 0
- Direct BIOSECURE
- 0
- Corp Events
- 1
- Gov-Connected
- 0
- Clinical Trials
- 1
- Publications
- 0
- Drug Molecules
- 0
- Relationships
- 1
Sources & Methodology
Clinical trials data: ClinicalTrials.gov API v2 (1 trials linked to this entity)
SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)
Publications: Europe PMC API (0 publications indexed)
Drug molecules: ChEMBL database (European Bioinformatics Institute)
Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)
Corporate structure: Company official filings, HKEX/SSE/SZSE disclosures
Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)
Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.